| Dr Alexander Lipman, MD | |
|
602 Jackson Street, Petoskey, MI 49770 | |
| (231) 348-2795 | |
| Not Available |
| Full Name | Dr Alexander Lipman |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 24 Years |
| Location | 602 Jackson Street, Petoskey, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386892560 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 4301099032 (Michigan) | Primary |
| 207L00000X | Anesthesiology | ME 110318 (Florida) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mclaren Northern Michigan | Petoskey, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Anesthesia Providers Pc | 4789579863 | 23 |
News Archive
Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that, in the treatment of atrial fibrillation, surveyed European cardiologists indicate that use of vitamin K antagonists, as a class, is primarily driven by the availability of an oral formulation, overall low cost and widespread inclusion on European medical society guidelines and hospital formularies.
As the first people with HIV grow old, a new study from St. Michael's Hospital questions whether the health care system and other government policies are prepared to meet their complex medical and social needs.
PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) ("PharmaGap" or "the Company") today announced that results are expected during September from the United States National Cancer Institute (NCI) follow-up study of the company's lead drug GAP-107B8.
Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.
The Company announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study to be presented at its March 25-26, 2011 conference. The presentation is entitled, "Management of Placebo Response in a Randomized Trial of KRN5500 in Patients with Neuropathic Pain and Cancer."
› Verified 9 days ago
| Entity Name | Northern Anesthesia Providers Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396834628 PECOS PAC ID: 4789579863 Enrollment ID: O20060405000243 |
News Archive
Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that, in the treatment of atrial fibrillation, surveyed European cardiologists indicate that use of vitamin K antagonists, as a class, is primarily driven by the availability of an oral formulation, overall low cost and widespread inclusion on European medical society guidelines and hospital formularies.
As the first people with HIV grow old, a new study from St. Michael's Hospital questions whether the health care system and other government policies are prepared to meet their complex medical and social needs.
PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) ("PharmaGap" or "the Company") today announced that results are expected during September from the United States National Cancer Institute (NCI) follow-up study of the company's lead drug GAP-107B8.
Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.
The Company announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study to be presented at its March 25-26, 2011 conference. The presentation is entitled, "Management of Placebo Response in a Randomized Trial of KRN5500 in Patients with Neuropathic Pain and Cancer."
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alexander Lipman, MD 301 Lafayette Ave, Apt A301, Petoskey, MI 49770 Ph: (786) 319-3519 | Dr Alexander Lipman, MD 602 Jackson Street, Petoskey, MI 49770 Ph: (231) 348-2795 |
News Archive
Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that, in the treatment of atrial fibrillation, surveyed European cardiologists indicate that use of vitamin K antagonists, as a class, is primarily driven by the availability of an oral formulation, overall low cost and widespread inclusion on European medical society guidelines and hospital formularies.
As the first people with HIV grow old, a new study from St. Michael's Hospital questions whether the health care system and other government policies are prepared to meet their complex medical and social needs.
PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) ("PharmaGap" or "the Company") today announced that results are expected during September from the United States National Cancer Institute (NCI) follow-up study of the company's lead drug GAP-107B8.
Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.
The Company announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study to be presented at its March 25-26, 2011 conference. The presentation is entitled, "Management of Placebo Response in a Randomized Trial of KRN5500 in Patients with Neuropathic Pain and Cancer."
› Verified 9 days ago
Dr. Mark James Bielaczyc, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 416 Connable Ave, Petoskey, MI 49770 Phone: 231-348-2795 Fax: 231-348-2031 | |
Dr. Paul Arthur Dowsett, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 416 Connable Ave, Petoskey, MI 49770 Phone: 231-348-2795 Fax: 231-348-2031 | |
Dr. Richard Arthur Tefo, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 602 Jackson St, Petoskey, MI 49770 Phone: 231-348-2795 Fax: 231-348-2031 | |
Dr. Kenneth James Cartwright, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 602 Jackson St, Petoskey, MI 49770 Phone: 231-348-2795 Fax: 231-348-2031 | |
Dr. David Alton Bell, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 416 Connable Ave, Petoskey, MI 49770 Phone: 231-348-2795 Fax: 213-348-2031 | |
William K Gretzinger, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 416 Connable Ave, Er Department, Petoskey, MI 49770 Phone: 231-487-4000 |